SEMA6A and melanoma: These finding are strongly in agreement with previous study showing that Sema6A represents, in melanoma cell line M14, one of the major modulated genes in response to MAPK inhibitor PD0325901 [38] and with our data showing that Vemurafenib treatment increases Sema6A expression in vemurafenib-resistant cells but inhibits Sema6A expression in the vemurafenib-responsive cells (unpublished data).